SLDB Company Profile and Key Details

SLDB has shown mixed momentum, gaining 7.25% over the past week and -4.42% over the past quarter, though year-to-date performance is down -0.35%. Short-term trend indicators are bearishly aligned (SMA20 0.3%, SMA50 5.24%, SMA200 16.25%). The stock’s 14-day RSI is 53.03 (neutral), while the ATR of 0.46 points to higher daily volatility. The stock remains hovering near 52-week lows, trading -14.65% below its high and over 161.0% above its low. Average 10-day trading volume of 773.62 thousand shares is below the 3-month average of 1.05 million, indicating normal recent market interest.

Solid Biosciences Inc. has 77.87 million shares outstanding. The public float is 37.61 million shares, elevated short interest at 14.93% of float. This equals 9.78 million shares. The short ratio is 6.72 days. Institutional investors hold 106.07% of the float. Insiders own 0.56%. PERCEPTIVE ADVISORS LLC holds 11.83 million shares, Bain Capital Life Sciences Investors, LLC has 5.03 million shares and Adage Capital Management, L.P. has 4.25 million shares. Over the past six months, insider transactions show net selling. They sold 427.62 thousand shares across 29 transactions.

Solid Biosciences Inc. generated EPS of -$2.49 over the past year. Five-year average earnings growth is 41.25%. Wall Street analysts project EPS growth of 14.41% annually over the next five years. The latest quarter delivered EPS of -$0.48. The next quarter is forecast at -$0.50. Next year's EPS is expected at $23.87. Analyst sentiment is bullish. Analyst rating data shows there are 6 Strong Buy ratings, 10 Buy ratings, 0 Hold ratings, 0 Sell rating and 0 Strong Sell ratings. Price targets range from $20.00 to $9.00. The high target offers 235.57% upside. The low target suggests 51.01% downside. The mean target is $14.69. This offers 146.48% upside. Solid Biosciences Inc. earnings surprise history is a mixed track record. The quarter that ended November 03, 2025, missed forecasts by 14.29%. The prior quarter beat by -17.65%. Over the last six quarters, Apple has recorded several small beats. These include -10.29% in August 13, 2024.

Solid Biosciences Inc. last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around $1.37. This means the shares are trading above this model’s fair value.

Solid Biosciences Inc. (NASDAQ:SLDB) closed at $5.96 USD, losing -$0.24 (-3.87%) from the previous close of $6.20. The stock is currently mid-range between its 52-week high and low $2.41 and $7.37. With a market capitalization of about $464.34 million, Solid Biosciences Inc. is classified as a small-cap and shows higher-than-market volatility (beta ~2.76). Key stats such as the average daily volume over the past year has been around 1.06 million shares, volume is running light vs its 52-week average. Headquartered in Cambridge, MA, Solid Biosciences Inc. operates in the Healthcare sector and the Biotechnology industry. Led by CEO Alexander G. Cumbo, the company employs approximately 100 people and listed since January 26, 2018. Solid Biosciences Inc. engages in developing therapies for duchenne muscular dystrophy in the United States.

Solid Biosciences Inc. (NASDAQ:SLDB) shares are flat -0.35% year-to-date currently trading near 52-week highs band. Short-term momentum has been negative over the last quarter, despite recent volatility. Valuation shows Solid Biosciences Inc. trading at a premium to the broader market with a P/E of -3.43. Analyst sentiment is bullish, with the majority of ratings in Buy territory and a mean price target of $13.98, suggesting 134.56% upside. Our AI forecast model points to short-term weakness (-2.52% over two weeks), a medium-term fall (-21.64% over three months), and a longer-term gain (199.66% over one year), with expected trading ranges indicating moderate volatility.

Our AI price prediction model suggests that Solid Biosciences Inc. stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected decline of -2.52%, with price expected at $5.81 by March 17, 2026, within a range of $5.37 to $6.21 3-Month Outlook: Projected fall of -21.64%, reaching $4.67 by June 01, 2026, with a range of $4.42 to $4.96. 1-Year Outlook: Projected gain of 199.66%, with price at $17.86 by March 03, 2027, within a range of $4.44 to $28.43.

Solid Biosciences Inc. trades at a P/E ratio of -3.43, slightly below the S&P 500 average, with a price-to-sales ratio of 0.0 and a price-to-book ratio of 2.63 suggesting the stock is closer to book value. The P/FCF stands at -3.55, also below market averages.